BridgeBio Pharma BBIO Cost of license, services, and royalty revenue — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
As of March 31, 2026 and December 31, 2025, there were $10.2 million and $5.0 million, respectively, of outstanding receivables relating to the Bayer License Agreement on our condensed consolidated balance sheets. During the three months ended March 31, 2026 and 2025, we recognized license and services revenue and royalty revenue of $10.3 million and $76.1 million, respectively, under the Bayer License Agreement. Our condensed consolidated balance sheet as of March 31, 2026 includes a deferred revenue balance of $2.7 million ($0.8 million presented as “Deferred revenue, current portion” and $1.9 million as “Deferred revenue, net of current portion”) related to our research and development services obligations. Our condensed consolidated balance sheet as of December 31, 2025, includes a deferred revenue balance of $2.9 million ($0.8 million presented as “Deferred revenue, current portion” and $2.1 million as “Deferred revenue, net of current portion”) related to our research and development services obligations.
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's cost of license, services, and royalty revenue — revenue?
- BridgeBio Pharma (BBIO) reported cost of license, services, and royalty revenue — revenue of $10.3M in Q1 2026.
- What does cost of license, services, and royalty revenue — revenue mean?
- This metric captures the total gross revenue generated specifically from the company's licensing of intellectual property, provision of specialized services, and receipt of royalty payments. It reflects the commercial success of the company's research and development efforts in monetizing its genetic disease and oncology pipeline through partnerships. This revenue stream is distinct from direct product sales and is a key indicator of the company's ability to leverage its scientific platform.
Ask your AI about BridgeBio Pharma's cost of license, services, and royalty revenue — revenue.
Connect your AI assistant and compare segments, right in your chat.
